Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 4 records in total 4
    records per page




    Treatment with Arbidol and Moxifloxacin in Ordinary and Severe Adult Patients Infected with COVID-19 MESHD

    Authors: DONGSHAN YU; SHUILIN SUN; YANHUA LI; WENNA XI; DI JIN; KE SUN; RONGYAN YU; XUEBING YAO; ZHIYING SONG; AOYU YANG; RUIXIA LUO; BIAOSHU ZOU; YUN LIU

    doi:10.1101/2020.05.30.20117598 Date: 2020-06-05 Source: medRxiv

    Background An outbreak of coronavirus disease 2019 MESHD ( COVID-19 MESHD) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widely spread. We aim to investigate the therapeutic effect of arbidol and moxifloxacin in patients infected with SARS-CoV-2. Methods We collected and analyzed data on 94 patients with COVID-19 MESHD including 27 severe patients at the Intensive Care Unit (ICU) and 74 ordinary patients at general isolation ward in Wuhan Xiehe Hospital, from February 15, 2020 to March 15, 2020. All patients were treated with arbidol (100mg each time, three times a day for 14 days) and moxifloxacin (0.4g each time, once a day for 7-14 days). Other data was also collected including demographic data, symptoms, laboratory findings, treatments and clinical outcomes. Results In basic characteristics, compared with the ordinary patients, the severe patients were older (median age was 63.0 years V.S 57.0 years, p=0.03), had higher proportion of hypertension MESHD (30% V.S 9%, p=0.03), higher possibility of getting fatigue and/or myalgia MESHD (26% V.S 6%, p=0.03), and had more obvious dyspnea MESHD symptom (26% V.S 3%, p=0.006). In regarding to laboratory results, we found the severe patients have higher white blood cell counts (p=0.003), neutrophil counts (p=0.007), higher levels of D-dimer (p<0.001), ALT (p<0.001) and AST HGNC (p=0.013) than the ordinary patients. After treatment of arbidol and moxifloxacin for one week, the rates of SARS-CoV-2 nucleic acid turning negative were 69.2% in the severe group and 77.8% in the ordinary group. A peculiar phenomenon was that IL-6 HGNC stands out among the cytokines in both groups, and higher in severe group than the ordinary one (p=0.011). After treating with arbidol and moxifloxacin for one week, IL-6 HGNC decreased significantly in severe group (p=0.023). Conclusion In summary, we proved the treatment of arbidol and moxifloxacin could be helpful in reducing viral load and inflammation MESHD during SARS-CoV2 infection MESHD, especially for negatively regulating fatal inflammation MESHD in severe COVID-19 MESHD patients. However, more evidence awaits further clinical verification.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Zeguang Zheng; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-28847/v1 Date: 2020-05-14 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with SARS-CoV-2, SARS-CoV MESHD, or MERS-CoV infection MESHD. Our data sources include PubMed, Embase, CNKI, and Ovid/Medline. The proportion of male patients with COVID-19 MESHD was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 MESHD had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence of hypertension MESHD (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore, the symptom of fever MESHD (53%), hemoptysis (1%), diarrhea MESHD (4%) and vomiting MESHD (3%) of COVID-19 MESHD were significantly lower than that in patients with SARS or MERS. The level of ALT and AST HGNC in COVID-19 MESHD was significantly lower (p<0.001), however, thrombocytopenia MESHD, high LDH were common. Summary, male, smoking history and hypertension MESHD were the most common risk factors for hospitalization with COVID-19 MESHD; and the clinical feature was less severe in COVID-19 MESHD.

    Clinical analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  infection in children

    Authors: Guilang Zheng; Chuxing Xie; Dongli Liu; Guojing Ye; Xiaoqian Chen; Pei Wang; Yang Zhou; Jiayi Liang; Dian Hong; Zhizhou Shen; Jinjin Yu; Yanhao Wang; Qiong Meng; Yuxin Zhang; Suhua Jiang; Guojun Liu; Yuxiong Guo

    doi:10.21203/rs.3.rs-21625/v1 Date: 2020-04-07 Source: ResearchSquare

    Background: The number of coronavirus disease 2019 MESHD ( COVID-19 MESHD) cases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD has significantly increased, and the disease is rapidly spreading to all parts of the country and around the world. A retrospective study of children with SARS-CoV-2 provides a reference for the diagnosis and treatment of children during this epidemic.Methods: We retrospectively studied 12 cases of children with viral infection MESHD caused by SARS-CoV-2 admitted to 6 hospitals in Guangdong Province between January 25, 2020, and February 12, 2020, and analyzed the clinical features and outcomes of the patients.Results: A total of 12 children with SARS-CoV-2 infection MESHD from 6 hospitals were enrolled in the study; 6 were boys. The mean age was 9.8 ± 4.7 years, with a minimum age of 2 years and 10 months. The mean body weight was 37.3 ± 23.6 kg, with a minimum body weight of 13.0 kg. There were no severe cases or critical severe cases. There were 2 cases of mild pneumonia MESHD (16.7%), 7 cases of acute upper respiratory tract infection MESHD (58.3%), and 3 cases of latent infection MESHD (25.0%). In terms of symptoms, there were 7 cases of fever MESHD (58.3%), 5 cases of cough (41.7%), 3 cases of runny nose (25.0%), 2 cases of systemic fatigue MESHD and soreness (16.7%), and 4 cases of no symptoms (33.3%). Three patients (75.0%) showed decreased white blood cell (WBC) counts for their first complete blood count (CBC) after admission, and one patient (8.3%) had a low lymphocyte count. There were no obvious abnormalities in C-reactive protein HGNC ( CRP, 1 HGNC.53 ± 2.28 mg/l), procalcitonin (PCT, 0.21 ± 0.13 ng/ml), or coagulation function. No abnormalities were detected for creatine kinase (CK), creatine kinase-MB (CKMB), lactate dehydrogenase (LDH), aspartate aminotransferase ( AST HGNC), alanine aminotransferase (ALT), blood urea nitrogen (BUN) and serum creatinine (Scr). Six cases (50.0%) were positive for Mycoplasma pneumoniae antibodies. 2 cases showed pulmonary exudative lesions on chest X-ray or computed tomography (CT). All children tested positive for SARS-CoV-2 by real-time reverse-transcription–polymerase-chain-reaction (RT-PCR) assays of throat swabs. 9 patients received antiviral treatment with lopinavir/ritonavir. All patients received symptomatic supportive treatment and were quarantined, and their conditions improved. There was no respiratory failure MESHD, acute respiratory distress syndrome MESHD, shock complications MESHD, or death observed for any case. All patients recovered and were discharged, with an average length of hospital stay of 14 days.Conclusions: This study with a small sample size suggests that all SARS-CoV-2-infected MESHD children had normal or reduced WBCs; however, fever MESHD was not as common as expected, and a decrease in lymphocyte count was rare. The clinical manifestations of SARS-CoV-2 infection MESHD in children are mild, COVID⁃19 is rare, and the prognosis is good. But the presence of latent SARS-CoV-2 infection MESHD in children presents new challenges for effective clinical prevention and control.

    Comparison of clinical characteristics and risk factors in hospitalized patients with SARS-CoV-2, MERS-CoV, and SARS-CoV infection

    Authors: Zhengtu Li; Xidong Wang; Guansheng Su; Shaoqiang Li; Yuwei Ye; Qiuxue Deng; Jinchuang Li; Xiaoyu Xiong; Xinguang Wei; Zeqiang Lin; Zichen Jie; Feng Ye

    doi:10.21203/rs.3.rs-21414/v1 Date: 2020-04-05 Source: ResearchSquare

    Herein, we compared the risk factors, clinical presentation of patients hospitalized with  SARS-CoV-2, SARS-CoV MESHD, or MERS-CoV infection MESHD. The proportion of male patients with COVID-19 MESHD was higher than who with SARS but lower than who with MERS (p<0.001). More patients with COVID-19 MESHD had coexisting chronic medical conditions than those with SARS (p<0.001) but fewer than those with MERS (p<0.001), and the prevalence of hypertension MESHD (17%) and smoking history (14%) was higher than in patients with SARS (p<0.001). Furthermore,the symptom of fever MESHD (53%), hemoptysis (1%), diarrhea MESHD (4%) and vomiting MESHD (3%) of COVID-19 MESHD were significantly lower than that in patients with SARS or MERS. The level of ALT and AST HGNC in COVID-19 MESHD was significantly lower (p<0.001), however, thrombocytopenia MESHD, high LDH were common. Summary, male, smoking history and hypertension MESHD were the most common risk factors for hospitalization with COVID-19 MESHD; and the clinical feature was less severe in COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.